Delving into the Latest Updates on FNI9 with Synapse

Overview

Basic Info

Drug Type

Polyclonal antibody

Synonyms

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza A virus infection

Inactive Indication-

Originator Organization

Vir Biotechnology, Inc.Humabs LLC

Active Organization

Vir Biotechnology, Inc.Humabs LLC

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Pizzuto, Matteo Samuele ; Virgin, Herbert W ; Cameroni, Elisabetta ; Zatta, Fabrizia ; Meury, Marcel ; Guarino, Barbara ; Yim, Samantha S ; Bartha, Istvan ; Chen, Alex ; Vyas, Siddhant ; Schmid, Michael A ; De Marco, Anna ; Donermeyer, David ; Momont, Corey ; Minola, Andrea ; di Iulio, Julia ; Telenti, Amalio ; Lanzavecchia, Antonio ; Corti, Davide ; Schaiff, William Timothy ; Rosen, Laura E ; Powell, Abigail E ; Wang, Caihong ; Ferri, Elena ; Balce, Dale R ; Miller, Jessica L ; Branch, Kaitlin ; Czudnochowski, Nadine ; Purcell, Lisa A ; Hauser, Kevin ; Spreafico, Roberto ; Dang, Ha V ; Croll, Tristan I ; Snell, Gyorgy ; Belnap, David M

Rapidly evolving influenza A viruses (IAVs) and influenza B viruses (IBVs) are major causes of recurrent lower respiratory tract infections. Current influenza vaccines elicit antibodies predominantly to the highly variable head region of haemagglutinin and their effectiveness is limited by viral drift¹ and suboptimal immune responses². Here we describe a neuraminidase-targeting monoclonal antibody, FNI9, that potently inhibits the enzymatic activity of all group 1 and group 2 IAVs, as well as Victoria/2/87-like, Yamagata/16/88-like and ancestral IBVs. FNI9 broadly neutralizes seasonal IAVs and IBVs, including the immune-evading H3N2 strains bearing an N-glycan at position 245, and shows synergistic activity when combined with anti-haemagglutinin stem-directed antibodies. Structural analysis reveals that D107 in the FNI9 heavy chain complementarity-determinant region 3 mimics the interaction of the sialic acid carboxyl group with the three highly conserved arginine residues (R118, R292 and R371) of the neuraminidase catalytic site. FNI9 demonstrates potent prophylactic activity against lethal IAV and IBV infections in mice. The unprecedented breadth and potency of the FNI9 monoclonal antibody supports its development for the prevention of influenza illness by seasonal and pandemic viruses.

100 Deals associated with FNI9

Login to view more data